In 282 treatment-naïve patients with CLL/SLL without del(17p), pirtobrutinib improved IRC-assessed PFS versus bendamustine plus rituximab (HR 0.199; 24-month PFS 93.4% vs 70.7%), with fewer grade ≥3 adverse events (40.0% vs 67.4%).
RCTn = 282 patients
Jurczak et al. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma